化学療法を受けている患者における 18F Florbetapir の心臓への取り込み

実験的：AL心筋アミロイド患者

登録された患者は、心臓ALアミロイドーシスの臨床診断を受けた18歳以上の患者です（典型的な心エコー検査またはMRI所見、332 pg / mLを超えるNT-ProBNPレベル、軽鎖アミロイドーシスの心臓または心臓外の組織学的証拠）。形質細胞指向の化学療法。

薬：F18 Florbetapir (amyvid) 心臓の PET/CT イメージング

計画された形質細胞指向の化学療法を受けている心臓アミロイドーシス（AL）の患者は、化学療法を開始する前と治療開始から6か月後にF-18フロルベタピル（アミビッド）心臓PET / CTイメージングを受けます。

他の名前：

• アミビッド

Relative Change in Cardiac Uptake of 18F Florbetapir Prior to Chemotherapy and After Six Months of Chemotherapy.

Levels of 18F florbetapir cardiac uptake at onset of chemotherapy will be compared with levels after six months of chemotherapy on repeat imaging.

Six Minute Walk Test

Change in Distance covered on six minute walk test at onset of chemotherapy will be compared to distance covered after six months of chemotherapy Distance at onset vs six months will be correlated with changes in 18F florbetapir cardiac uptake on cardiac PET/CT imaging between 0 and 6 months. Overall change in distance walked during 6 minute walk prior to starting chemotherapy and after 12 months of chemotherapy will be compared to any changes in 18F florbetapir cardiac uptake on cardiac PET/CT imaging between 0 and 6 months.

Hematologic Response

correlation of hematologic response to treatment at 6 months and 18F florbetapir cardiac uptake changes between 0 and 6 months. Hematologic response after 12 months will also be compared to any changes in 18F florbetapir cardiac uptake between 0 and 6 months.

Cardiac Response

Cardiac response as defined by changes in NT proBNP (N Terminal proBNP) levels and cardiac Troponin T levels will be correlated with changes in 18F florbetapir cardiac uptake between 0 and 6 months. Changes in Cardiac troponin T and NT pro BNP levels after 12 months will also be correlated with changes in 18F florbetapir cardiac uptake between 0 and 6 months.

Patient Related Outcomes

Correlation of hematologic response to results of patient related outcomes survey completed at 0, 6, and 12 months.

Patient reported outcomes survey was developed using PROMIS short form v2.0-Physical Function 8b, PROMIS short form v1.0 Dyspnea Severity 10a, and PROMIS short form v1.0 Fatigue 8a. Measures used in the patient survey were obtained from the health measures website at www.healthmeasures.net/promis, which can be accessed for further information. Scale 1-5 with one being not at all and 5 being very likely.

Patient Related Outcomes

Correlation of cardiac response to results of patient related outcomes survey completed at 0, 6, and 12 months

Patient reported outcomes survey was developed using PROMIS short form v2.0-Physical Function 8b, PROMIS short form v1.0 Dyspnea Severity 10a, and PROMIS short form v1.0 Fatigue 8a. Measures used in the patient survey were obtained from the health measures website at www.healthmeasures.net/promis, which can be accessed for further information. Scale 1-5 with one being not at all and 5 being very likely.

Patient Related Outcomes

Correlation changes in 18F florbetapir cardiac uptake between 0 and 6 months to results of patient related outcomes survey completed at 0, 6, and 12 months

Patient reported outcomes survey was developed using PROMIS short form v2.0-Physical Function 8b, PROMIS short form v1.0 Dyspnea Severity 10a, and PROMIS short form v1.0 Fatigue 8a. Measures used in the patient survey were obtained from the health measures website at www.healthmeasures.net/promis, which can be accessed for further information. Scale 1-5 with one being not at all and 5 being very likely.